SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is drawing intense community focus after reports that it plans to monetize excess AI compute capacity through a new cloud offering, a strategic shift that has sparked heated debate over whether it signals genuine revenue diversification or underlying desperation regarding capital expenditure. Traders are actively clashing over the long-term impact on the AI infrastructure ecosystem, as the stock faces volatile price action driven by conflicting narratives about compute scarcity versus potential overcapacity.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is experiencing intense volatility as investors weigh the company's aggressive pivot toward AI infrastructure against the reality of legacy revenue declines and heavy debt. While the community is actively debating the durability of its fiber footprint and the potential for a transformative 'J-curve' revenue inflection, the stock's price action is being heavily driven by mechanical forces like index rebalancing and short-term speculative trading.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is experiencing significant volatility and trading momentum following a 13G filing revealing that Michael Platts BlueCrest Capital Management has taken a 5.6% stake. The community is actively debating whether this institutional interest signals a sustainable growth phase for the company's humanoid robotics ambitions or if the move is merely a short-term catalyst in an otherwise speculative SPAC environment.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant volatility and aggressive profit-taking, fueling a heated debate among investors about whether this marks a fundamental trend reversal or a healthy correction within the broader semiconductor cycle. While the community remains polarized, many are closely monitoring key support levels to determine if the stock will stabilize or face further downside following its recent parabolic run.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is facing intense volatility as the stock experiences a sharp, sector-wide sell-off that the community is actively debating as either a fundamental breakdown or a temporary liquidity reset. While some investors are aggressively buying the dip on the belief that demand for optical infrastructure remains intact, others are warning of further technical deterioration and downward pressure as the stock struggles to find a stable support floor.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is experiencing a sharp sell-off driven by speculative fears regarding competition from satellite-based connectivity services and recent regulatory headlines. While the community is actively debating the long-term impact of satellite technology on fiber infrastructure, many investors are viewing the current price as a generational buying opportunity for the company's dividend yield and long-term value.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is facing intense selling pressure as investors react to a significant executive compensation package that lacks immediate performance milestones, coupled with broader market volatility in the AI infrastructure sector. The community is deeply divided between long-term bulls who view the current price drop as an aggressive accumulation opportunity and vocal critics who are questioning management's capital allocation and execution speed.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending as investors debate its pivot toward AI infrastructure and high-performance computing, with sentiment heavily divided by management's strategic communication and dilution concerns. The community is actively discussing the stock's volatility relative to Bitcoin's price movements and the potential for a long-term turnaround based on pending data center tenant deals.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals is trending following positive interim Phase 1/2a results for its ARO-INHBE and ARO-ALK7 obesity programs, which demonstrated significant potential as combination therapies to enhance weight and visceral fat loss. The community is actively discussing the clinical data's impact on Arrowhead's long-term valuation and pipeline competitiveness, with many investors debating the company's potential as a major acquisition target.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF is experiencing a notable rotation as investors shift capital into the sector, driven by institutional reweighting and optimism regarding M&A activity despite recent market volatility. The community remains focused on the potential for clinical trial readouts and sector-wide recovery, with active debate regarding the sustainability of the current momentum and the impact of broader market index rebalancing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received a successful response to its recent Type C meeting request from the...

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational...

Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and...

Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning...

Lantern Pharma Unveils Roadmap for withZeta.ai Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm and ZetaOmics

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, today unveiled the next phase of its development roadmap for withZeta.ai, the companys multi-agentic A.I...

Lantern Pharmas predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company advancing precision oncology through its proprietary RADR AI platform, today announced the expansion of predictBBB.ai into a...

Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), an AI-driven clinical-stage precision oncology company, today announced the first public demonstration of withZeta.ai, its multi-agentic...

Emerging Data for Lantern Pharmas Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure With No Added Toxicity

Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for mid-May 2026 to...

Lantern Pharma Launches withZeta.ai the Worlds First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22

Lantern Pharma Inc. (Nasdaq: LTRN) (Lantern or the Company), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai the worlds first and most comprehensive...

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Lantern Pharma Inc

Top Pre-Market Gainers Today — ELAB, ITRM, LTRN Among Stocks Soaring Before The Bell

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

LTRNLantern Pharma Inc

Fundamentals

Latest LTRN News